Pricing Log in Create free account

Avalyn Pharma Inc. (AVLN) vs Inhibrx Biosciences, Inc. (INBX)

Avalyn Pharma Inc. and Inhibrx Biosciences, Inc. are both Biotechnology companies. Avalyn Pharma Inc. and Inhibrx Biosciences, Inc. are of similar size ($1.2B and $1.2B). Across the 7 metrics below, Inhibrx Biosciences, Inc. leads on 4 and Avalyn Pharma Inc. on 3.

Valuation

Metric AVLN INBX Biotechnology median
P/E n/m n/m 10.60
P/S n/m 424.97 9.40
P/B 2.16 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 438.60 9.02
Earnings yield (357.99%) (10.39%) (32.88%)
Free cash flow yield (11.24%) (9.85%) (23.13%)

Profitability

Metric AVLN INBX Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (1,773.60%) (51.96%)
Return on assets (43.95%) (75.44%) (46.06%)
Return on invested capital (102.61%) 0.00% 0.00%

Growth

Metric AVLN INBX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) — (108.03%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AVLN INBX Biotechnology median
Debt to equity 0.04 (3.33) 0.00
Current ratio 33.12 5.07 4.97
Net debt to EBITDA — 0.18 1.01

Dividend

Metric AVLN INBX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AVLN INBX Biotechnology median
Market cap 1.18b 1.18b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack